Answer
Breastfeeding should be discontinued during ripretinib (QINLOCK) treatment and for at least one week after the final dose because excretion into human milk is unknown and a risk to the breastfed child cannot be excluded.
Sources for this answer
- QINLOCK 50 mg tabletsDeciphera · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 2Document updated
Sources checked